Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.69 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320212 | 0.96 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2313138 | 0.95 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2318032 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2317837 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL30336051 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL4399789 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2315888 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2320342 | 0.82 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL30335916 | 0.82 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL2317734 | 0.82 | MAPK14 (1.00) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349964-B1 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C A I R BIOSCIENCES GMBH (DE) | 2015-09-09 | — | — | EP | disclosed |
| EP-2349964-B1 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C A I R BIOSCIENCES GMBH (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-8633312-B2 | Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds | C-A-I-R BIOSCIENCES GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633312-B2 | Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds | C-A-I-R BIOSCIENCES GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633312-B2 | Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds | C-A-I-R BIOSCIENCES GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2349964-A2 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | c-a-i-r biosciences GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010040843-A2 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010040843-A2 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | IL1B, NFKBIA, IL1R1 | MAPK14 2812/4885MAPK13 2654/4885HSPB1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.